Owlstone Medical Wins Contract for Handheld Breath Biopsy Device
The U.S. Department of Defense awarded the contract with the goal of developing and providing a device that can be used in the field.
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics.' The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.
Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging. Under these conditions, the risk of contracting a respiratory disease, and subsequently its spread to other personnel, is high and can have a severe impact on mission readiness. Most current diagnostic testing platforms are unsuitable to be deployed in the field, and so there is a significant need for a portable solution.
This story continues here.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
